Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
How this was made
The 30-second read
Why it matters
The call updates both financial guidance (NERLYNX revenue, royalty revenue, net income) and clinical execution (amended ALISCA-Breast1 dosing, enrollment counts and planned starts for lung studies), creating multiple near-to-medium term catalysts.
Market read
Traders get fresh, quantified guidance for NERLYNX and net income, plus updated clinical trial enrollment and interim-data timing that can drive sentiment into Q3 and Q4.
What to watch
Clinical catalysts are delayed into Q3 enrollment and Q4 updated interim data, so near-term sentiment may hinge more on NERLYNX than alisertib progress.
Background
Puma Biotechnology is advancing alisertib Phase II programs (ALISCA-Breast1, ALISCA-Lung1, and planning ALISCA-Lung2) while commercializing NERLYNX (neratinib).
Ticker impact
Puma raised 2026 NERLYNX net product revenue to $205M-$209M and net income to $17M-$20M, plus updated Phase II alisertib enrollment plans.
Likely supportive for shares on guidance strength, with additional upside tied to updated interim alisertib data in Q4.
The article provides concrete 2026 and Q3 financial outlook ranges and specific clinical protocol changes (dose groups, FDA/Europe submission, enrollment start in Q3).
Market effects
Biopharma oncology sentiment may improve modestly for targeted-kinase programs as Puma signals funding capacity for Phase III based on projections.
Limited direct regional read-through; guidance is company-specific with China royalty mechanics as a secondary factor.
NERLYNX China sublicense royalty threshold risk highlights global IP and generic-competition dynamics for branded oncology drugs.
Counterpoint
Raised revenue and income outlook could be offset by lower royalty revenue expectations and potential China market-share threshold effects later in 2026-2027.
Key entities
- companyPuma Biotechnology
Raised 2026 NERLYNX net product revenue and net income outlook; amended alisertib Phase II protocols and provided enrollment/data timing.
- drugalisertib
Investigational oncology agent in Phase II trials ALISCA-Breast1 and ALISCA-Lung1, with ALISCA-Lung2 planned.
- productNERLYNX (neratinib)
Commercial oncology therapy whose 2026 and Q3 revenue and royalty outlook were updated.
